We describe a 63-year-old woman with a diagnosis of breast cancer who relapsed with multiple bone lesions 18 years later. The biological characteristics were estrogen receptor positive, progesterone receptor positive, and HER2-positive cancer. Lapatinib and letrozole was the treatment of choice as a manageable and active first-line therapy for this patient.
GeyerC.E., ForsterJ., LindquistD., ChanS., RomieuC.G., PienkowskiT., Jagiello-GruszfeldA., CrownJ., ChanA., KaufmanB., SkarlosD., CamponeM., DavidsonN., BergerM., OlivaC., RubinS.D., SteinS., CameronD.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355: 2733–2743, 2006.
2.
CameronD., CaseyM., PressM., LindquistD., PienkowskiT., RomieuC.G., ChanS., Jagiello-GruszfeldA., KaufmanB., CrownJ., ChanA., CamponeM., ViensP., DavidsonN., GorbounovaV., RaatsJ.I., SkarlosD., NewstatB., RoychowdhuryD., PaolettiP., OlivaC., RubinS., SteinS., GeyerC.E.: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 112: 533–543, 2008.
3.
CapriG., ChangJ., ChenS-C, ConteP., CwiertkaK., JerusalemG., JiangZ., JohnstonS., KaufmanB., LinkJ., RoJ., SchütteJ., OlivaC., ParikhR., PrestonA., RosenlundJ., SelzerM., ZembrykiD., De PlacidoS.: An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or MBC. Ann Oncol, 21: 474–480, 2010.
4.
JohnstonS., PippenJ.Jr., PivotX., LichinitserM., SadeghiS., DierasV., GomezH.L., RomieuG., ManikhasA., KennedyM.J., PressM.F., MaltzmanJ., FloranceA., O'RourkeL., OlivaC., SteinS., PegramM.: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive MBC. J Clin Oncol, 27: 5538–5546, 2009.
5.
SchwartzbergL.S., FrancoS.X., FloranceA., O'RourkeL., MaltzmanJ., JohnstonS.: Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive MBC. Oncologist, 15: 122–129, 2010.
6.
KaufmanB., MackeyJ.R., ClemensM.R., BapsyP.P., VaidA., WardleyA., TjulandinS., JahnM., LehleM., FeyereislovaA., RévilC., JonesA.: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive MBC: results from the randomized phase III TAnDEM study. J Clin Oncol, 27: 5529–5537, 2009.
7.
OsborneK., NevenP., DirixL.: Randomized phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive MBC. Breast Cancer Res Treat, 106: S1–S107(Abstr. 2067), 2007.
8.
OsborneK., NevenP., DirixL., MackeyJ., RobertJ., UnderhillC., SchiffR., GutierrezC., MigliaccioI., AnagnostouV., RimmD., MagillP., SellersM.: Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor–positive MBC: a randomized phase II study. Clin Cancer Res, 17: 1147–1159, 2011.
9.
CristofanilliM., ValeroV., MangalikA., RoyceM., RabinowitzI., ArenaF.P., KroenerJ.F., CurcioE., WatkinsC., BacusS., CoraE.M., AndersonE., MagillP.J.: Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive MBC. Clin Cancer Res, 16: 1904–1914, 2010.
